Bioengineering human intestinal mucosal grafts using patient-derived organoids, fibroblasts and scaffolds

Meran, Laween; Tullie, Lucinda; Eaton, Simon; Coppi, Paolo De; Li, Vivian

doi:10.1038/s41596-022-00751-1

Cited by 14 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A protocol for bioengineering human intestinal grafts was designed by Meran et al. [ 137 ] Decellularized human intestinal scaffolds were generated from natural tissues and provided a cell regeneration system to form transplantable constructs.…”

Section: Exploring Modes Of Organoid Engineering: Prospects For Devel...mentioning

confidence: 99%

Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction

Jin,

Xue,

Liu

et al. 2024

Biomater Res

View full text Add to dashboard Cite

Tissue damage and functional abnormalities in organs have become a considerable clinical challenge. Organoids are often applied as disease models and in drug discovery and screening. Indeed, several studies have shown that organoids are an important strategy for achieving tissue repair and biofunction reconstruction. In contrast to established stem cell therapies, organoids have high clinical relevance. However, conventional approaches have limited the application of organoids in clinical regenerative medicine. Engineered organoids might have the capacity to overcome these challenges. Bioengineering—a multidisciplinary field that applies engineering principles to biomedicine—has bridged the gap between engineering and medicine to promote human health. More specifically, bioengineering principles have been applied to organoids to accelerate their clinical translation. In this review, beginning with the basic concepts of organoids, we describe strategies for cultivating engineered organoids and discuss the multiple engineering modes to create conditions for breakthroughs in organoid research. Subsequently, studies on the application of engineered organoids in biofunction reconstruction and tissue repair are presented. Finally, we highlight the limitations and challenges hindering the utilization of engineered organoids in clinical applications. Future research will focus on cultivating engineered organoids using advanced bioengineering tools for personalized tissue repair and biofunction reconstruction.

show abstract

Section: Exploring Modes Of Organoid Engineering: Prospects For Devel...mentioning

confidence: 99%

Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction

Jin,

Xue,

Liu

et al. 2024

Biomater Res

View full text Add to dashboard Cite

show abstract

“…ECM gels play the role of structural support and offering ECM signals, and common ECM gels include basement membrane extract, Matrigel, and Geltrex. The main components of the medium for the submerged culture include adDMEM/F12, penicillin/streptomycin, GlutaMAX, HEPES, B27, epidermal growth factor (EGF), FGF2, FGF10, Wnt3A, Noggin, R‐spodin‐1, Prostaglandin E2, N‐Acetylcysteine, Nicotinamide, Y27632, A‐8301, and SB202190 37,99 . The medium composition varies when forming organoids from different tissues, and which specific factors need to be added or removed usually depends on the requirements of the tissue from which they originate for the corresponding signal or hormone 100 …”

Section: Culture Approaches Of Organoidsmentioning

confidence: 99%

Organoids: The current status and biomedical applications

Yang

Kung

et al. 2023

MedComm

View full text Add to dashboard Cite

Organoids are three‐dimensional (3D) miniaturized versions of organs or tissues that are derived from cells with stem potential and can self‐organize and differentiate into 3D cell masses, recapitulating the morphology and functions of their in vivo counterparts. Organoid culture is an emerging 3D culture technology, and organoids derived from various organs and tissues, such as the brain, lung, heart, liver, and kidney, have been generated. Compared with traditional bidimensional culture, organoid culture systems have the unique advantage of conserving parental gene expression and mutation characteristics, as well as long‐term maintenance of the function and biological characteristics of the parental cells in vitro. All these features of organoids open up new opportunities for drug discovery, large‐scale drug screening, and precision medicine. Another major application of organoids is disease modeling, and especially various hereditary diseases that are difficult to model in vitro have been modeled with organoids by combining genome editing technologies. Herein, we introduce the development and current advances in the organoid technology field. We focus on the applications of organoids in basic biology and clinical research, and also highlight their limitations and future perspectives. We hope that this review can provide a valuable reference for the developments and applications of organoids.

show abstract

“…76 This result may make an important contribution to the personalized treatment in the future. 77 van Tienderen and his colleagues 78 seeded patient-derived cholangiocarcinoma (CCA) organoids (CCAOs) onto the decellularized CCA matrix (CCA-M) to explore the detailed role of tumor ECM in CCA progression. They observed that the expression of stem cell markers, such as LGR5, CD44, and Wnt target gene CLDN2, was downregulated in the CCA-M-cultured CCAOs.…”

Section: Decellularized Cancer Matrix-based Applicationsmentioning

confidence: 99%

“…In this study, the organoids were preferentially grown on a scaffold obtained from the neoplastic peritoneal, characterized by a greater stiffness than the normal scaffold 76 . This result may make an important contribution to the personalized treatment in the future 77 . van Tienderen and his colleagues 78 seeded patient‐derived cholangiocarcinoma (CCA) organoids (CCAOs) onto the decellularized CCA matrix (CCA‐M) to explore the detailed role of tumor ECM in CCA progression.…”

Section: Decellularized Cancer Matrixmentioning

confidence: 99%

Decellularized diseased tissues: current state‐of‐the‐art and future directions

Li,

Shan,

Chen

et al. 2023

MedComm

View full text Add to dashboard Cite

Decellularized matrices derived from diseased tissues/organs have evolved in the most recent years, providing novel research perspectives for understanding disease occurrence and progression and providing accurate pseudo models for developing new disease treatments. Although decellularized matrix maintaining the native composition, ultrastructure, and biomechanical characteristics of extracellular matrix (ECM), alongside intact and perfusable vascular compartments, facilitates the construction of bioengineered organ explants in vitro and promotes angiogenesis and tissue/organ regeneration in vivo, the availability of healthy tissues and organs for the preparation of decellularized ECM materials is limited. In this paper, we review the research advancements in decellularized diseased matrices. Considering that current research focuses on the matrices derived from cancers and fibrotic organs (mainly fibrotic kidney, lungs, and liver), the pathological characterizations and the applications of these diseased matrices are mainly discussed. Additionally, a contrastive analysis between the decellularized diseased matrices and decellularized healthy matrices, along with the development in vitro 3D models, is discussed in this paper. And last, we have provided the challenges and future directions in this review. Deep and comprehensive research on decellularized diseased tissues and organs will promote in‐depth exploration of source materials in tissue engineering field, thus providing new ideas for clinical transformation.

show abstract

Bioengineering human intestinal mucosal grafts using patient-derived organoids, fibroblasts and scaffolds

Cited by 14 publications

References 70 publications

Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction

Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction

Organoids: The current status and biomedical applications

Decellularized diseased tissues: current state‐of‐the‐art and future directions

Contact Info

Product

Resources

About